Back to top

Is Tandem Diabetes Care (TNDM) Stock Outpacing Its Medical Peers This Year?

Read MoreHide Full Article

Investors focused on the Medical space have likely heard of Tandem Diabetes Care (TNDM - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

Tandem Diabetes Care is one of 818 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. TNDM is currently sporting a Zacks Rank of #2 (Buy).

Within the past quarter, the Zacks Consensus Estimate for TNDM's full-year earnings has moved 0.18% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

According to our latest data, TNDM has moved about 1,418.22% on a year-to-date basis. At the same time, Medical stocks have gained an average of 11.58%. As we can see, Tandem Diabetes Care is performing better than its sector in the calendar year.

Looking more specifically, TNDM belongs to the Medical - Instruments industry, which includes 92 individual stocks and currently sits at #90 in the Zacks Industry Rank. This group has gained an average of 27.81% so far this year, so TNDM is performing better in this area.

Investors in the Medical sector will want to keep a close eye on TNDM as it attempts to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Tandem Diabetes Care, Inc. (TNDM) - free report >>

More from Zacks Tale of the Tape

You May Like